Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Medicinal Chemistry|June 11, 2014
Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activityXitao Li, Yingying Zuo, Guanghui Tang, et al.Oncotarget|May 7, 2015
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphomaNing Ding, Xitao Li, Yunfei Shi, et al.International Journal of Cancer|September 15, 2017
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphomaJiao Li, Xiaogan Wang, Yan Xie, et al.Proceedings of the National Academy of Sciences of the United States of America|May 28, 2005
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitisKristina K Hansen, Philip M Sherman, Laurie Cellars, et al.Oncotarget|April 21, 2017
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophagesLingyan Ping, Ning Ding, Yunfei Shi, et al.Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyLee A Honigberg, Ashley M Smith, Mint Sirisawad, et al.The Journal of Biological Chemistry|April 27, 2017
Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesisXiaoqing Cheng, Yuan Hao, Wenjie Shu, et al.Cancer Cell International|March 1, 2019
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphomaYalu Liu, Xiaogan Wang, Lijuan Deng, et al.Pageof 4